retatrutide obesity trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished TRIUMPH-3 π¦πΊ retatrutide cardiovascular/obesity clinical
Pay in 4 interest-free payments of $6.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 23 - Aug 28


























